Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
334 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03212404 | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | active not recruiting | Phase 1 | 272 | Checkpoint Therapeutics, Inc.INDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT03649971 | A Study of Guselkumab in Participants With Familial Adenomatous Polyposis | completed | Phase 1 | 77 | Janssen Research & Development, LLCINDUSTRY | 9 | Feb 3, 2025 | clinicaltrials |
| NCT05496231 | A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age | completed | Phase 1 / Phase 2 | 1,080 | GlaxoSmithKlineINDUSTRY | 8 | Feb 3, 2025 | clinicaltrials |
| NCT02240238 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | completed | Phase 1 / Phase 2 | 119 | NanoCarrier Co., Ltd.INDUSTRY | 5 | Jan 22, 2025 | clinicaltrials |
| NCT03504488 | CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) | completed | Phase 1 / Phase 2 | 132 | BioAtla, Inc.INDUSTRY | 6 | Jan 15, 2025 | clinicaltrials |
| NCT04727554 | Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors | completed | Phase 1 | 11 | AmgenINDUSTRY | 10 | Jan 6, 2025 | clinicaltrials |
| NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 117 | Hoffmann-La RocheINDUSTRY | 6 | Dec 18, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT03994211 | Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer | completed | Phase 1 | 25 | BeiGeneINDUSTRY | 4 | Oct 26, 2024 | clinicaltrials |
| NCT04521621 | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | terminated | Phase 1 / Phase 2 | 76 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Oct 1, 2024 | clinicaltrials |
| NCT04500587 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | completed | Phase 1 | 39 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT05002868 | Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors | completed | Phase 1 | 23 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT06593145 | CAR T Cells in the Treatment of Refractory and Relapsed CD19+ B Cell Neoplasms(CARLA) | recruiting | Phase 1 | 6 | FamiCordTxINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03154827 | Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 1 | BioLineRx, Ltd.INDUSTRY | 6 | Sep 5, 2024 | clinicaltrials |
| NCT04594811 | NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma | terminated | Phase 1 | 10 | NeoImmuneTechINDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT02509507 | Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611(MASTERKEY-318) | completed | Phase 1 / Phase 2 | 127 | AmgenINDUSTRY | 9 | Aug 6, 2024 | clinicaltrials |
| NCT02554812 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | terminated | Phase 1 / Phase 2 | 409 | PfizerINDUSTRY | 8 | Jul 30, 2024 | clinicaltrials |
| NCT02920697 | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 65 | Institut de Recherches Internationales ServierOTHER | 8 | Jul 25, 2024 | clinicaltrials |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | terminated | Phase 1 | 172 | TG Therapeutics, Inc.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT04915404 | Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) | terminated | Phase 1 / Phase 2 | 5 | WPD Pharmaceuticals Sp. z o.o.INDUSTRY | 1 | Jun 6, 2024 | clinicaltrials |
| NCT03711604 | Compassionate Use Study of Tenalisib (RP6530) | completed | Phase 1 / Phase 2 | 17 | Rhizen Pharmaceuticals SAINDUSTRY | 3 | May 8, 2024 | clinicaltrials |
| NCT05240131 | A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC). | unknown | Phase 1 / Phase 2 | 88 | Galecto Biotech ABINDUSTRY | 3 | Apr 12, 2024 | clinicaltrials |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma(FIDES-03) | terminated | Phase 1 / Phase 2 | 47 | Basilea PharmaceuticaINDUSTRY | 15 | Apr 4, 2024 | clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 70 | Kartos Therapeutics, Inc.INDUSTRY | 12 | Mar 22, 2024 | clinicaltrials |
| NCT00516373 | A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) | completed | Phase 1 | 98 | AstraZenecaINDUSTRY | 4 | Feb 22, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT03219268 | A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms | completed | Phase 1 | 277 | MacroGenicsINDUSTRY | 8 | Dec 21, 2023 | clinicaltrials |
| NCT04151563 | A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy(CheckMate 79X) | withdrawn | Phase 1 / Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 19, 2023 | clinicaltrials |
| NCT03980314 | A Study to Compare Nivolumab Drug Product Process D to Nivolumab Drug Product Process C in Participants With Stage IIIa/b/c/d or Stage IV Melanoma After Complete Resection | completed | Phase 1 | 261 | Bristol-Myers SquibbINDUSTRY | 14 | Dec 15, 2023 | clinicaltrials |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | terminated | Phase 1 | 6 | Vincerx Pharma, Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT01234025 | Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC) | completed | Phase 1 / Phase 2 | 113 | Ionis Pharmaceuticals, Inc.INDUSTRY | 6 | Oct 6, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT02825836 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | unknown | Phase 1 / Phase 2 | 130 | Telios Pharma, Inc.INDUSTRY | 7 | Jul 13, 2023 | clinicaltrials |
| NCT02740712 | Pharmacokinetic Drug-Drug Interaction Study of Rucaparib(DDI) | completed | Phase 1 | 17 | pharmaand GmbHINDUSTRY | 1 | Jun 9, 2023 | clinicaltrials |
| NCT03521037 | Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor | completed | Phase 1 | 16 | pharmaand GmbHINDUSTRY | 3 | Jun 9, 2023 | clinicaltrials |
| NCT03954366 | Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | completed | Phase 1 | 36 | pharmaand GmbHINDUSTRY | 3 | Jun 8, 2023 | clinicaltrials |
| NCT02983045 | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors(PIVOT-02) | completed | Phase 1 / Phase 2 | 557 | Nektar TherapeuticsINDUSTRY | 8 | Mar 13, 2023 | clinicaltrials |
| NCT05259397 | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 2 | Mar 8, 2023 | clinicaltrials |
| NCT03312530 | A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 49 | Hoffmann-La RocheINDUSTRY | 9 | Feb 28, 2023 | clinicaltrials |
| NCT05176691 | HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL | withdrawn | Phase 1 | 0 | HutchmedINDUSTRY | 7 | Feb 21, 2023 | clinicaltrials |
| NCT04514159 | A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | completed | Phase 1 | 14 | Zeno Alpha Inc.INDUSTRY | 2 | Feb 1, 2023 | clinicaltrials |
| NCT03388749 | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 20 | Moleculin Biotech, Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | terminated | Phase 1 | 35 | Aileron Therapeutics, Inc.INDUSTRY | 7 | Oct 10, 2022 | clinicaltrials |
| NCT05518526 | Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases(ANNA-SARC) | unknown | Phase 1 / Phase 2 | 64 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Aug 26, 2022 | clinicaltrials |
| NCT02361346 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL(MT-3724NHL001) | terminated | Phase 1 / Phase 2 | 38 | Molecular Templates, Inc.INDUSTRY | 10 | Aug 18, 2022 | clinicaltrials |
| NCT04502394 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | recruiting | Phase 1 / Phase 2 | 84 | Kartos Therapeutics, Inc.INDUSTRY | 11 | Aug 4, 2022 | clinicaltrials |
| NCT02404441 | Phase I/II Study of PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 319 | Novartis PharmaceuticalsINDUSTRY | 14 | Aug 3, 2022 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials